Kornimate/medical-research-clean huggingface dataset:
effect of vojta therapy on motor control in children with attention deficit hyperactivity disorder

Conditions: Attention Deficit Disorder With Hyperactivity

Summary: adhd is generally associated with significant comorbidities including motor disorders in up to 96% of cases. within these, disturbances of balance and motor coordination that interfere with school learning and daily activities are present in 47% of school children with adhd. therefore, the aim of this research is to determine whether vojta therapy is beneficial for the improvement of balance, postural control, hand-eye coordination and manipulative motor skills in children with adhd, hyperactive and/or combined, aged 6-12 years.


Eligibility criteria:
inclusion criteria: 1. have a diagnosis of attention deficit hyperactivity disorder (adhd) of the combined or hyperkinetic type. 2. be between 6 and 12 years of age. 3. be under treatment with methylphenidate. 4. iq of 100 or higher. 5. have a normal neurological examination. 6. not dysmorphic. 7. not have received specific physiotherapy treatment for the improvement of balance and postural control in the two months prior to inclusion in the study. exclusion criteria: 1. present a diagnosis of adhd comorbid with other neuropsychiatric pathologies. 2. have a history of neurological or musculoskeletal disorders that are linked to a deficit in balance and/or postural control. 3. be under treatment with atomoxetine.

Keywords: attention-deficit/hyperactivity disorder vojta therapy balance postural control visual motor coordination manipulative skills
evaluation of the clinical effectiveness and safety of acellular dermal matrix(sc derm® recon) in breast reconstruction

Conditions: Breast Cancer Female; Breast Reconstruction

Summary: this is the multi-centered, open, prospective and retrospective study of up to total 120 subjects in breast reconstruction surgery with applying acellular dermal matrix(adm). the aim of the study is to ascertain any difference in the rate of complications between the test group of undergoing breast reconstruction with sc derm and the control group of taking breast reconstruction with other adm products.

in south korea, breast reconstruction surgery using implants or autologous abdominal tissue is commonly performed as the standard treatment to address the aesthetic and psychological needs of breast cancer patients who have undergone total mastectomies. in this procedure, acellular dermal matrix (adm) is used to compensate for the skin deficit resulting from the removal of cancerous tissue. this clinical study is designed to ascertain whether there are differences in clinical efficacy, aesthetic outcomes, and safety in breast reconstruction surgery using adm processed with supercritical carbon dioxide technology compared to other adms. the test group will be prospectively selected in 60 patients who undergo the breast reconstruction surgery applying with sc derm(inverstigational adm processed by the supercritical technology). the control group will be retrospectively collected in 60 patients who underwent the breast reconstruction surgery applying with other adm from the current medical records for one year of 2022.

Eligibility criteria:
inclusion criteria: * female patients aged 20 to 69 scheduled for total mastectomy * patients who are willing to undergo immediate breast reconstruction using implants. exclusion criteria: * patients who have undergone organ transplantation and are currently taking immunosuppressive medication. * patients with mental conditions that could impact the conduct of the clinical study, such as alcohol or drug abuse. * patients who have participated in another clinical trial within 120 days prior to screening. * any other cases where the investigator deems the patient unsuitable for this clinical study.

Keywords: acellular dermal matrix(adm) breast reconstruction using implants and adm
concussion screen use recovery time

Conditions: Sport-related Concussion

Summary: a two-year parallel randomized clinical trial study to examine the effect of screen time (st) restriction, exercise alone, and combined st-restricted-exercise when compared to stretching only (control group) on sports related concussion recovery time among adolescents aged 12 to 17 years. study hypothesis 1 - there will be significant differences between the treatment and the control arms' mean recovery time (days). study hypothesis 2 - the st-restricted \& exercise treatment arm will have a significantly shorter mean recovery time (days) compared with the other treatment arms and control arm.

the investigators will randomize a sports related concussion (src) treatment protocol (n=313) of children's health andrews institute for orthopaedics and sports medicine (andrews) pediatric src patients (aged 12-17 years) to one of four treatment groups:1. screen time (st) restricted group, 2.exercise group, 3.st restricted \& exercise group, and control \[stretching only\]) group. the treatments will occur for the first 72-hours following the first clinic appointment. the investigators will monitor treatment adherence and 24-hour movement behaviors over a 72-hour period using the actigraph gt9x link and heart rate monitor; a state-of-the-art research grade wearable device that our research team has expertise in administering and analyzing in field-based studies.

Eligibility criteria:
inclusion criteria: * male or female subjects * age 12-17 years of age presenting to the children's health andrews institute for orthopaedics and sports medicine (andrews) concussion clinic in plano, texas, to be treated for a diagnosed src * patients who suffered a sport-related concussion within 72-hours of first clinic visit exclusion criteria: * patients who suffered a sport-related concussion outside of 72-hours of first clinic visit * is not diagnosed with a src * is already taking part in another study that measures their physical activity, sleep, screen-time, or is related to concussion * has a current diagnosis of and treatment with medication for attention deficit/hyperactivity disorder, learning disorder, depression, anxiety, or a history of more than 3 prior concussions (because these factors are associated with delayed recovery * has a co-existing musculoskeletal injury that may impact their ability to be physically active during recovery * has an increased cardiac event risk according to the american college of sports medicine criteria * has a symptom severity score of less than 5 points on the post-concussion symptom scale during the initial clinical examination * has an ability to exercise to exhaustion without symptom provocation during the initial clinical examination * has limited english language proficiency

Keywords: concussion sports related head injury
an extended facebook intervention for young sexual and gender minority smokers

Conditions: Tobacco Use; Smoking; Tobacco Dependence; Tobacco Use Disorder; Tobacco Use Cessation; Tobacco Smoking; Smoking Cessation; Smoking, Cigarette; Smoking, Tobacco

Summary: the 2-year research plan will test the extended put it out project (pop-6) in a pilot randomized trial (n=168) compared to tsp-6, as well as comparing pop-6 and tsp-6 to the pop-3 and tsp-3 interventions from a previously-conducted trial. participants will be young adults who smoke, identify as sexual or gender minorities (sgm), and use facebook. primary outcome will be biochemically verified 7-day abstinence from smoking at 3 and 6 months. secondary outcomes will be a quit attempt (y/n), stage of change, and thoughts about tobacco abstinence at 3 and 6 months.

participants will be randomized to one of two conditions: (1) a 6-month facebook-delivered intervention addressing tobacco use, tailored to sgm young adults; or (2) a 6-month facebook intervention targeting tobacco use. both interventions will include 180 days of facebook-based messages and activities tailored to participants' readiness to quit smoking. assessments will occur at baseline, 3, and 6 months follow-up. assessments will include measures on smoking, thoughts about abstinence, and sgm identity experiences. all participants who report no past 7-day smoking will be asked to give biochemical verification of smoking status with saliva nicotine test kits that will be mailed to participants.

Eligibility criteria:
inclusion criteria: * read english * between 18 and 25 years of age * indicate they use facebook "most" (≥ 4) days per week * have smoked ≥100 cigarettes in their lives and currently smoke at least 1 cigarette per day on 4 or more days of the week * identifies as sgm * lives in california exclusion criteria: * do not read english * are not between 18 and 25 years of age * indicate they do not use facebook "most" (≥ 4) days per week * have not smoked ≥100 cigarettes in their lives and currently smoke at least 1 cigarette per day on 4 or more days of the week * does not identify as sgm * does not live in california

Keywords: tobacco gender identity minority sexual identity minority cessation intervention young adults social media internet cigarette
sustained viral response in chronic hepatitis b patients who achieved hbeag seroncongversion after interferon therapy

Conditions: Chronic Hepatitis B

Summary: chronic hepatitis b (chb) is a serious liver disease worldwide, and the leading cause of cirrhosis and hepatocellular carcinoma (hcc). hbeag seroconversion is considered to be the satisfied endpoint of antiviral therapy in hbeag-positive chronic hepatitis b patients. however, hbv reaction, even reverse back to hbeag positive and clinical relapse could occur in some patients who achieved hbeag seronconversion by interferon treatment. in this study, the long-term efficacy of interferon therapy in hbeag positive patients achieved hbeag seronconversion after interferon treatment and the factors associated with viral and clinical relapse will be observed.

hbeag positive chronic hepatitis b patients achieved hbeag seronconversion by interferon treatment will be enrolled and observed for 156 weeks. serum hbv dna, hbsag, anti-hbs, hbeag, and anti-hbe will be measured every 3 months during the observation period, liver function tests were performed every 3 months also. the liver ultrasonic examination would be taken every 3-6 months. the primary endpoint is sustained viral response, and secondary endpoints is hbv dna reaction and clinical relapse defined as virla relapse with abnormal alt during observation period.

Eligibility criteria:
inclusion criteria: * patients who achieved hbeag seroconversion by interferon treatment. exclusion criteria: * active consumption of alcohol and/or drugs * co-infection with human immunodeficiency virus, hepatitis c virus, or hepatitis d virus * history of autoimmune hepatitis * psychiatric disease * evidence of neoplastic diseases of the liver

Keywords: hbeag positive interferon peginterferon hbeag seroconversion sustained viral response relapse
myoelectric computer interface to reduce muscle co-activation after stroke

Conditions: Stroke

Summary: this study examines whether in-lab training with a myoelectric-computer interface (myci) can reduce abnormal muscle co-activation after stroke.


Eligibility criteria:
inclusion criteria: * stroke survivors at least 6 months after stroke onset * persistent moderate to severe arm impairment * increased arm tone exclusion criteria: * substantial impairment of vision, memory, language or concentration * botulinum toxin use in the affected arm * concomitant participation in another research study on the arm
fibered platinum coils vs vascular plugs in pelvic varices embolization for the treatment of pelvic congestion syndrome

Conditions: Pelvic Congestion Syndrome

Summary: this prospective randomized study compares the safety and efficacy of two different embolizing agents for the treatment of pelvic congestion syndrome: fibered platinum coils and vascular plugs.

this prospective randomized study compares the safety and efficacy of two embolizing agents for the treatment of pelvic congestion syndrome: fibered platinum coils (nester coils; cook medical) and vascular plugs (amplatzer vascular plugs ii; st. jude medical).

Eligibility criteria:
inclusion criteria: * signed informed consent * presence of chronic abdominal or pelvic pain for more than 6 months * \>6 mm pelvic venous caliber measured by transvaginal us * presence of venous reflux or presence of communicating veins assessed by transvaginal doppler us exclusion criteria: * diagnosed gynecological or pelvic pathology: endometriosis, pelvic inflammatory disease, postoperative adhesions, adenomyosis or leiomyoma * glomerular filtration rate \<60 ml/min * history of contrast reaction * patients not able to be followed up for at least one year

Keywords: pelvic congestion syndrome pelvic venous insufficiency chronic pelvic pain
trial of methyl b12 on behavioral and metabolic measures in children with autism

Conditions: Autistic Disorder

Summary: the purpose of this study is to determine whether the supplement methyl b12 is effective in treating some of the symptoms of autism.

autism is a complex neurodevelopmental disorder with early childhood onset characterized by impairments in communication, social interaction, and repetitive behavior. due to the lack of known treatments for autism, many parents seek complementary and alternative medical (cam) therapies hoping to help their affected child. methylcobalamin (methyl b12) is a commonly used cam treatment that has anecdotal reports of remarkable clinical improvements with few side effects. prior studies have found that children with autism have deficiencies in key metabolites and antioxidants which can be caused by methyl b12 deficiency; additional studies have shown that methyl b12 normalizes deficiencies in these metabolites and antioxidants. based on these reports, a pilot study was conducted at uc davis on the effect of methyl b12 on the behavioral and metabolic measures in children with autism. the preliminary results of 29 subjects revealed a subgroup of 9 responders to clinical behavior assessments. these responders also demonstrated significant improvement on the plasma measures of antioxidant capacity, suggesting methyl b12 improves symptoms in a subgroup of children with autism by increasing key antioxidants. the current study will have an 8 week double blind design with 50 subjects, designed to evaluate improvements from methyl b12 by using behavioral assessments and analysis of specific metabolites in the subjects' blood. this study will determine whether methyl b12 will lead to benefits in any of the core features of autism, and will examine metabolic changes with the hope of potentially identifying a biomarker for treatment response in a subgroup of subjects.

Eligibility criteria:
inclusion criteria: * diagnosis of dsm iv defined autism and meets cut off on autism diagnostic inventory-revised (adi-r) and/or the autism diagnostic observation scale (ados) * age 3 through 7 years * iq of 50 or above * parental agreement to continue present dietary, behavioral or psychotropic drug treatment but not change treatment during 8 week intervention * willingness to have blood drawn, without the use of a sedative prescription from the study doctor exclusion criteria: * bleeding disorder * cancer * seizure disorder * fragile x or other known genetic cause of autism * perinatal brain injury (i.e.: cerebral palsy) * other serious medical illnesses * current use of any b12 supplement

Keywords: autism pervasive developmental disorders
impact of a loading dose of caspofungin in invasive candidiasis in icu patients

Conditions: Candida Infections

Summary: echinocandins are the drug of choice in severe candida infections. efficacy of echinocandins is related to concentration and area under the curve (auc) of the drug. available pharmacokinetic studies found that concentration of echinocandins mainly caspofungin is sub-optimal in severe candida infections in intensive care unit (icu) patients. higher dose of caspofungin has been proven to be safe in critically ill patients but its impact on the ability to reach pk/pd target is unknown. the aim of this study is to evaluate the impact of a loading dose of caspofungin on pk/pd parameters within the first 24-hours.

invasive fungal infections are associated to a high mortality rate in icu, partly because of a delayed treatment. pk/pd targets for caspofungin are the peak concentration over minimal inhibitory concentration (mic) ratio which should reach 10 and the area under the inhibitory curve (auic) which should be over 200. high distribution volume in icu patients and increase of mics due to extensive use of antifungal agents make optimal concentration difficult to obtain. high doses up to 150mg of caspofungin have been reported to be safe. thus, in our unit, a loading dose of 140mg of caspofungin is a standard practice but was never rigorously evaluated. the aim of the present study is to measure the impact of a loading dose of 140mg of caspofungin on the pharmacokinetic parameters in the first 24 hours of treatment. the auic and maximal concentration (cmax) / (mic) according to the recovered yeasts will be measured. the investigators also planned a monte-carlo simulation using mics obtained from clinically relevant candida strains isolated in bichat and grenoble hospitals in order to evaluate the percentage of patients appropriately treated within the first 24 hours according to candida species and previous use of antifungals. recovered strains from epidemiological studies will be used for pkpd modelling and will use s. a second monte-carlo simulation will be done using data from the amarcand 2 study. all mics will be determined using e-test ( biomerieux® kit's) without specifying any breakpoints as mics and not breakpoints per se will be used.

Eligibility criteria:
inclusion criteria: * patient hospitalized in intensive care * age\> 18 years * patient with a central catheter * patient with invasive mechanical ventilation * patient receiving more than 0.1 mcg / kg / min of adrenaline or noradrenaline * patient treated for proven (positive blood cultures or positive specimen obtained during a surgical or percutaneous puncture) or suspected (risk factor, extra digestive colonization, absence of other uncontrolled bacterial infections, candida score\> 3) invasive candidiasis. * patient affiliated to medical insurance exclusion criteria: * expected length of stay under 48h * age \<18 years * pregnant or breastfeeding women * limited or sustained life support therapy * patient unable to legally consent * history of allergy, hypersensitivity or intolerance to echinocandins or drug excipients
effects of sleep deprivation on food intake and motor activity in man

Conditions: Healthy

Summary: evidence that shortened period of sleep could be a risk factor for weight gain and obesity has grown over the past decade. concurrent with the obesity epidemic, numerous studies have reported a parallel epidemic of chronic sleep deprivation. sleep is important in maintaining energy balance (i.e. acute sleep deprivation impact the normal secretion of ghrelin and decreases leptin plasma levels). surprisingly, in humans, there is no direct evidence that a shortened night has direct effect on energy metabolism during the following day. this study is set up to determine whether a partial sleep deprivation night has an impact on appetite and food energy intake and, concomitantly, on physical activity, during the following day.


Eligibility criteria:
inclusion criteria: * male * age between 18 and 30 * healthy * non smoker * less than 5 hour of sport per week * bmi between 20 and 25 kg/m/m exclusion criteria: * eating disorders, * dieting or fasting * restrained (score \>9), disinhibited (score \>11) or hungry subjects (score \>9), according to the three-factor eating questionnaire general healthiness, * food-snacking (more than twice a day),

Keywords: sleep deprivation food intake motor activity normal, healthy subjects
biphasic defibrillation study: trial to compare fixed versus escalating energy

Conditions: Cardiac Arrest

Summary: this study will compare the effect of constant low-level energy \[150 joules\] to an escalating energy \[200-300-360 joules\] regimen of biphasic waveform defibrillation on multiple patient outcomes.

this pilot, which will enroll 200 subjects, will allow a reasonable estimate of effect size and this will, in turn, allow for the accurate design and planning of a definitive randomized controlled trial. the following outcomes will be evaluated: 1. important clinical outcomes: * successful conversion, * resuscitation to one hour, * survival to hospital discharge, * neurological function, and * quality of life. 2. process outcomes: * number of shocks required, * recurrences of vf, and * responsiveness to varying periods of pulselessness. 3. adverse outcomes: * myocardial damage.

Eligibility criteria:
inclusion criteria: * witnessed cardiac arrest out-of-hospital requiring defibrillation and given by first responder using an automated external defibrillator exclusion criteria: * terminal illness or do-not-resuscitate (dnr) status * no cardiopulmonary resuscitation (cpr) x 10 minutes * acute trauma * exsanguination * cardiac arrest experienced while in hospital

Keywords: defibrillation ventricular fibrillation heart arrest
a prospective, monocentric clinical study for the validation of in vitro diagnostic tests developed by firalis

Conditions: Genetic Health Risks

Summary: firalis sa and its affiliate amoneta diagnostics sas are developing novel in-vitro-diagnostic (ivd) tests for diverse diagnostic applications for major human diseases, including cardiovascular, and neurodegenerative disorders. these tests detect several gene mutations related to the above-mentioned pathologies. the development of ivd tools requires the evaluation of analytical parameters including biomarker stability. the present specific study therefore aims to collect whole blood samples in paxgene dna tubes to complete the analytical validation of ivd tools and the evaluation of the stability of the dna in paxgene dna tubes and the reagents in the ivd tools.


Eligibility criteria:
inclusion criteria: * donors who sign the informed consent forms for sample collection and for genotyping. * adults, both genders, aged 18-85 years. * not under any administrative or legal supervision exclusion criteria: * anyone who did not sign the informed consent form. * subjects aged below 18 years and older than 85 years are excluded. * pregnant, parturient and nursing women are excluded

Keywords: polygenic risk apoe, apolipoprotein neurodegenerative disorders dementia alzheimer disease genetic risks
preemptive analgesia of gabapentoids in orthopedic surgery

Conditions: Acute Postoperative Pain

Summary: to address the preemptive analgesic effect of preoperative gabapentoids versus no gabapentoids in orthopedic surgery

computer search for all studies used preoperative gabapentoids versus no gabapentoids in orthopedic surgery during the last 10 years (from 2011 - 2020)

Eligibility criteria:
inclusion criteria: * rct, during last 10 years, involving orthopedic surgery exclusion criteria: * non randomized trials, unavailable study data

Keywords: acute postoperative pain preemptive analgesia orthopedic surgery preoperative gabapentoids